MBOAT7

MBOAT7 rs641738 — When Phospholipid Remodeling Falters, the Liver Pays the Price

Your liver cells constantly remodel the fatty acid tails of membrane phospholipids,
swapping in and out different acyl chains to maintain proper membrane composition
and signaling. The MBOAT7 gene | membrane-bound O-acyltransferase domain-containing 7,
also known as LPIAT1 (lysophosphatidylinositol acyltransferase 1)
encodes the enzyme responsible for one specific and critical step in this process:
re-acylating lysophosphatidylinositol (lyso-PI) | a phospholipid stripped of its
sn-2 fatty acid tail with arachidonoyl-CoA to produce PI(18:0/20:4), the
dominant phosphatidylinositol species in hepatocyte membranes. The rs641738 variant
reduces MBOAT7 expression in the liver, depleting this key phospholipid and tipping
the balance toward hepatic fat accumulation and inflammation.

The Mechanism

MBOAT7 operates within the Lands cycle | a phospholipid remodeling pathway where
phospholipase A2 cleaves the sn-2 fatty acid from a phospholipid, creating a
lysophospholipid, and an acyltransferase re-esterifies it with a new fatty
acid. What makes MBOAT7 unique among
the MBOAT family is its exquisite substrate selectivity: it preferentially
esterifies arachidonoyl-CoA (C20:4, an omega-6 fatty acid) into the sn-2 position
of lyso-PI. This selectivity means MBOAT7 is the primary enzyme determining how
much arachidonic acid ends up in phosphatidylinositol pools.

The rs641738 T allele sits in the regulatory region between MBOAT7 and TMC4 on
chromosome 19. It does not change the MBOAT7 protein sequence, but it reduces
MBOAT7 mRNA and protein expression in hepatocytes. Lipidomic profiling of human
liver biopsies shows that T allele carriers have markedly reduced PI species
containing arachidonoyl chains — primarily PI(18:0/20:4) — and elevated levels
of the precursor 18:0-lyso-PI and 18:1-lyso-PI | Luukkonen et al. The MBOAT7
variant rs641738 alters hepatic phosphatidylinositols and increases severity
of non-alcoholic fatty liver disease in humans. J Hepatol, 2016.
The functional consequence is a deficit in arachidonoyl-PI, which disrupts
membrane signaling, lipid droplet dynamics, and inflammatory tone in the liver.

When MBOAT7 activity falls, the accumulation of lyso-PI and the depletion of
mature PI species promote de novo lipogenesis and triglyceride accumulation in
hepatocytes. MBOAT7 also appears to shape the availability of arachidonic acid
for downstream eicosanoid production, linking phospholipid remodeling to
inflammatory signaling in Kupffer cells and hepatic stellate cells.

The Evidence

The variant was first identified as a NAFLD risk locus in the landmark study by
Mancina et al. | The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic
Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016,
which examined 3,854 participants in the multi-ethnic Dallas Heart Study and 1,149
European liver biopsy patients. Each T allele increased risk of hepatic steatosis
(OR 1.42 in the biopsy cohort), NASH (OR 1.18), and significant fibrosis (OR 1.30).
In European Americans specifically, the per-allele OR for steatosis was 1.37.

The definitive evidence came from a meta-analysis of 42 studies encompassing over
one million participants (9,688 with liver biopsies) | Teo et al. rs641738C>T near
MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.
J Hepatol, 2021. This analysis
confirmed that the T allele increases risk of NAFLD diagnosis (OR 1.17), advanced
fibrosis under a recessive model (OR 1.22), and elevated ALT, while lowering serum
triglycerides. Crucially, the association was robust in European adults but was not
replicated in children or in non-European populations, suggesting the effect may
be modulated by environmental or developmental factors.

Beyond NAFLD, rs641738 T increases risk of liver inflammation and accelerated
fibrosis progression in chronic hepatitis C | Thabet et al. MBOAT7 rs641738
increases risk of liver inflammation and transition to fibrosis in chronic
hepatitis C. Nat Commun, 2016 (n=2,051),
and increases hepatocellular carcinoma risk in non-cirrhotic patients with liver
disease | Donati et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in
non-cirrhotic individuals. Sci Rep, 2017
(OR 2.10 in combined non-cirrhotic cohort).

The effect size of rs641738 is modest compared to PNPLA3 rs738409 (the strongest
NAFLD risk variant), but it acts through an independent pathway — phospholipid
remodeling rather than triglyceride hydrolysis — making it a complementary risk
factor with additive effects when combined with PNPLA3 and TM6SF2 risk alleles.

Practical Actions

For T allele carriers, the key insight is that your liver's phosphatidylinositol
remodeling is compromised. MBOAT7 preferentially incorporates arachidonic acid
(an omega-6 PUFA) into PI, and when this process is impaired, the ratio of
omega-6 to omega-3 fatty acids in hepatic membranes shifts. Dietary strategies
that increase EPA and DHA intake can partially compensate by providing alternative
substrates for membrane phospholipid composition and by dampening the inflammatory
signaling that MBOAT7 deficiency amplifies.

Monitoring liver enzymes (ALT, GGT) is particularly relevant because the T allele
independently raises ALT. A mildly elevated ALT in a TT homozygote may reflect
the genetic predisposition rather than acute liver injury, but it also signals
that the liver is under more metabolic stress than the same ALT value would
indicate in a CC individual.

Interactions

MBOAT7 rs641738 interacts additively with PNPLA3 rs738409 and TM6SF2 rs58542926.
In a multicenter biopsy-based study of 515 NAFLD patients | Krawczyk et al.
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738
variants on NAFLD severity. J Lipid Res, 2017,
the three variants contributed through distinct mechanisms: PNPLA3 drove both
steatosis and fibrosis, TM6SF2 primarily steatosis, and MBOAT7 selectively
fibrosis (OR 1.77 in multivariate analysis). Increasing numbers of risk alleles
across all three loci correlated with progressively higher liver enzymes.

The MTARC1 protective variant (rs2642438) operates in a complementary pathway —
while MBOAT7 deficiency impairs phospholipid remodeling, MTARC1 loss-of-function
enhances hepatic fat oxidation. Carriers of MBOAT7 risk alleles who also carry
MTARC1 protective alleles may experience partial offset of their fibrosis risk,
though this specific interaction has not yet been directly quantified.

HSD17B13 rs72613567 (a protective splice variant) also interacts with MBOAT7
risk through complementary mechanisms: HSD17B13 loss-of-function reduces
hepatic lipid droplet toxicity while MBOAT7 deficiency increases it, making
the presence or absence of HSD17B13 protection relevant for MBOAT7 risk carriers.